Sales Trigger: Sail Biomedicines Board Hire

🚀 Battle Card: Sail Biomedicines

• Martin Mackay, Ph.D., Board of Directors Member

• This Sail Biomedicines sales trigger underscores the need for top-tier R&D and board-level expertise to fast-track in vivo CAR-T clinical entry. → Source

• Lack of board-level clinical development guidance for novel CAR-T platforms

• Pressure to integrate AI-driven eRNA design with scalable delivery systems

• Primary: Board advisory services → Accelerated IND submission & clear regulatory roadmap

• Expansion: AI-powered R&D integration platform → Reduced design-to-clinic timelines & costs

• HQ: Cambridge, MA

• Employees: ≈ 150

• Rev: ≈ $10M

• Website: sail.bio

🤼 Competitive Intel

• Moderna — RNA Therapeutics
• Unique edge: Proven mRNA delivery tech with clinical approvals
• Evaluated by VP R&D for platform reliability

• Alnylam Pharmaceuticals — RNAi Therapeutics
• Unique edge: Advanced delivery systems and safety track record
• Evaluated by Board for long-term partnership potential

• Charles River Laboratories — Preclinical CRO
• Unique edge: End-to-end in vivo study capabilities in GLP settings
• Evaluated by Head of Preclinical for study design expertise

• Thermo Fisher Scientific — Cell Therapy Manufacturing
• Unique edge: Scalable CAR-T manufacturing & supply chain support
• Evaluated by VP Manufacturing for capacity and speed

• Lonza — Gene & Cell Therapy CDMO
• Unique edge: Global GMP facilities & rapid tech transfer
• Evaluated by VP Ops for operational flexibility

✅ Do-Now Checklist

Next Step

🧠 Copy My Prompt for Personalized Cold Outreach

────────────────────────────
✏️ YOUR COMPANY
────────────────────────────
OUR_COMPANY   = ❑❑
OFFER_BRIEF   = ❑Board advisory services for CAR-T development❑
PROOF_METRIC  = ❑reduced IND submission time by 30%❑
CTA_STYLE     = ❑quick_call❑
TONE          = ❑friendly❑

────────────────────────────
📌 TARGET COMPANY
────────────────────────────
NAME        = Martin
COMPANY     = Sail Biomedicines
DEPT        = Board of Directors
SIZE        = ≈ 10
BOTTLENECK  = lack of board-level clinical development guidance
EVENT       = Board appointment
DETAIL      = appointment of Martin Mackay to the Board
PAIN        = lack of board-level clinical development guidance for novel CAR-T platforms
SRC         = http://cts.businesswire.com/ct/CT?id=ftfLlWd9aZbF2NXfwppam3Bd664=&newsLang=en&newsId=20251023185582&div=41152219
SIM_CO      = ≈ TBD
WIN_METRIC  = ≈ TBD
NEXT_SIZE   = ≈ TBD
EMP_EST     = ≈ 150
REV_EST     = ≈ $10M

────────────────────────
TASK FOR CHATGPT
────────────────────────
Role: “NewsletterForLeads SDR-Assist”.

Validate any ≈ guesses via SRC.

EMAIL  (keep breaks):
Subject: ≈ 10-person Board of Directors

Martin—noticed your Board of Directors team is ≈ 10.

That’s when lack of board-level clinical development guidance slows growth.

We helped ≈ TBD fix this with Board advisory services for CAR-T development.

Result: ≈ TBD.  
Quick call?

PS—next bottleneck hits ≈ TBD.

DM ≤45 words, TONE:
Saw your post about appointment of Martin Mackay to the Board — lack of board-level clinical development guidance for novel CAR-T platforms.  
Board advisory services for CAR-T development. reduced IND submission time by 30%.  
Quick chat?```